Phenobarbital Sodium

苯巴比妥钠

Report date: 2023/01/13 20:00:32
NME

Base Information

Drug NamePhenobarbital Sodium
Drug Alias Namefenobarbital de sodio苯巴比妥的单钠盐phenobarbitalum natricumLupialLuminal +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGamma-aminobutyric acid A receptor agonists
TargetsGamma-aminobutyric acid A receptor
Therapy Area/IndicationsSedationHyperbilirubinemiaNeonatal Abstinence Syndrome +[11] 
Global Approved IndicationsSedationHyperbilirubinemiaSleep Initiation and Maintenance Disorders +[5] 
Approved Indications in ChinaHyperbilirubinemiaSleep Initiation and Maintenance DisordersSeizures
Original Approved Country/TerritoryJapan
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPuerto Rico +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesYouhua Pharmaceutical (Leshan) Co LtdDi'Ao Group Chengdu Pharmaceutical Co LtdTianjin Pharmaceutical Peace (Tianjin) Pharmaceutical Co Ltd +[4] 
Inactive CompaniesUniversity of ZurichNema Research IncPharpoint Research Inc +[5] 
Active IndicationsSedationHyperbilirubinemiaSleep Initiation and Maintenance Disorders +[6] 
Inactive IndicationsNeonatal Abstinence SyndromeInfant, Newborn, DiseasesPremature Birth +[5] 

Other Information

ATC CodeN03AA02
Related LinksWikipediaDrugBankKEGG